Screener
Incyte INCY Accrued Manufacturing Costs
Accrued Manufacturing Costs at other companies
Other financials
Where this comes from
Reported directly by Incyte in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The source filing: Incyte’s 10-Q, filed July 28, 2026.
- Filed
- Jul 28, 2026, 4:02 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000879169-26-000056
| Line item | June 30,2026 | December 31,2025* |
|---|---|---|
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $250,401 | $209,938 |
| Accrued compensation | 148,319 | 228,071 |
| Accrued and other current liabilities | 870,306 | 1,031,501 |
| Finance lease liabilities | 4,259 | 4,516 |
| Acquisition-related contingent consideration | 38,811 | 41,144 |
| Total current liabilities | 1,312,096 | 1,515,170 |
Item 1. Financial Statements
FAQ
- What is Incyte's accrued manufacturing costs?
- Incyte (INCY) reported accrued manufacturing costs of $148.32M in Q2 2026.
- How has Incyte's accrued manufacturing costs changed year-over-year?
- Incyte's accrued manufacturing costs increased by 14.9% year-over-year, from $129.11M to $148.32M.
- What is the long-term trend for Incyte's accrued manufacturing costs?
- Over 5 years (2020 to 2025), Incyte's accrued manufacturing costs has grown at a 15.0% compound annual growth rate (CAGR), from $113.34M to $228.07M.
Ask your AI about Incyte's accrued manufacturing costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude